Business Wire

SUNTEC-GROUP

9.12.2021 06:26:14 CET | Business Wire | Pressemeddelelse

Del
SEB, Nordens førende erhvervsbank, vælger SunTecs pakke med løsninger til en koncernomspændende udrulning for at automatisere næste generation af tilbud til fakturering-programmet

SunTec Business Solutions, verdens førende prisfastsættelses- og faktureringsvirksomhed, meddelte i dag, at virksomheden er blevet valgt af Nordens førende erhvervsbank, SEB, til en koncernomspændende global udrulning og til at automatisere deres næste generation af tilbud-til-fakturering-program. SunTecs pakke med løsninger vil digitalisere bankens salgsproces, fra aftalehåndtering og prisfastsættelse til fakturering.

SEB valgte SunTec som teknologipartner til at hjælpe med at opfylde deres vigtigste strategiske initiativer for at blive førende inden for kundeoplevelser, skabe robusthed og fleksibilitet i banken og øge aktiviteterne for store erhvervs- og finansinstitutioner samt SMV'er.

Olle Durelius, Co-Head Transaction Services hos SEB, fortæller, "Vores ambition er at opgradere vores eksisterende processer, og vi er meget glade for at have indgået et partnerskab med SunTec og starter denne rejse for at forbedre og fremme digitalisering og automatisering. Vi var på udkig efter en løsningsudbyder, der kunne understøtte transformationen af vores aktiviteter. I SunTec fandt vi en ligesindet partner, der kunne hjælpe os med at digitalisere vores salgsproces, sikre hurtigere time-to-market, stoppe indtægtslækager, reducere manuel indgriben og sikre, at vi fakturerer klienterne i overensstemmelse med deres forventninger. Med SunTecs pakke med løsninger og platformen Xelerate vil vi understøtte vores aktiviteter inden for likviditetsstyring samt globale depotydelser og "sub-custody" til en start."

Nanda Kumar, grundlægger og CEO hos SunTec, udtaler, "Vi er meget glade for at have indgået et partnerskab med SEB for at styrke deres position som rådgiver til erhvervsklienter, forbedre driftsmæssig fortræffelighed og sikre digital distribution af deres tilbud. Vores robuste pakke med løsninger udrullet på vores Xelerate-platform vil tilbyde en teknologisk infrastruktur, der er API-venlig, modulopbygget af natur, og som automatiserer deres tilbud til fakturering-livscyklus. Denne aftale er en milepæl for os i Norden og viser, at banker i stigende grad skal gå mod en arkitektur i tre lag og udnytte et intelligent midterlag for at sikre agilitet og kundecentrering."

Om SunTec

SunTec er verdens førende prisfastsættelses- og faktureringsvirksomhed, der skaber værdi for virksomheder via cloudbaserede produkter. Mere end 130 klienter i over 45 lande stoler på, at SunTec kan levere meget personligt tilpassede produkter, tilbud, prisfastsættelse, loyalitetsprogrammer og fakturering for mere end 400 millioner slutkunder. SunTecs produkter er baseret på vores cloud-native og cloud-agnostiske, API first, mikrotjenestebaserede proprietære platform, Xelerate, og leveres på stedet, på privat cloud og som SaaS. SunTec har globale aktiviteter, der omfatter USA, Storbritannien, Tyskland, Forenede Arabiske Emirater, Singapore, Canada, Australien og Indien. Besøg www.suntecgroup.com for at få flere oplysninger, eller send en e-mail til os på marketing@suntecgroup.com .

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release

Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc

Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release

Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response

PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release

Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye